The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

Condor Partners and Northlight Capital Partners, with JP Partners brokering the deal, are pleased to announce new funding for Mural Park, a 200,000-square-foot, Class A office project in Chicago, ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

The DESTINY-Breast09 Phase III trial of AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab ...

Topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed Enhertu in combination with pertuzumab ...

Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but ...

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is ...